Two Sigma Investments
CLYM

Two Sigma Investments’s Climb Bio CLYM Stock Holding History

Two Sigma Investments’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Sell
310,606
-256,106
-45% -$1.48M ﹤0.01% 2711
2025
Q4 		$2.27M Buy
566,712
+454,031
+403% +$1.09M ﹤0.01% 2345
2025
Q3 		$226K Sell
112,681
-66,910
-37% -$124K ﹤0.01% 3335
2025
Q2 		$223K Sell
179,591
-75,523
-30% -$94K ﹤0.01% 2880
2025
Q1 		$311K Buy
255,114
+17,404
+7% +$28.2K ﹤0.01% 2701
2024
Q4 		$428K Buy
237,710
+214,196
+911% +$775K ﹤0.01% 2599
2024
Q3 		$120K Buy
+23,514
New +$166K ﹤0.01% 2877

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Two Sigma Investments's CLYM Position: Q1 2026 in Review

Two Sigma Investments reduced its Climb Bio (CLYM) stake by 45% in Q1 2026, selling an estimated $1.48M and leaving 310,606 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Two Sigma Investments first reported a position in CLYM in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.27M in Q4 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Two Sigma Investments held 310,606 shares of Climb Bio worth $2.13M as of Q1 2026.
  • Two Sigma Investments sold 256,106 Climb Bio shares in Q1 2026, an estimated $1.48M.
  • Climb Bio made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2711 holding.
  • Two Sigma Investments first reported a position in Climb Bio in Q3 2024 and has held it in 7 quarters since.
  • Two Sigma Investments's Climb Bio position peaked at $2.27M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.